Lothar Krinke


Lothar has been the CEO of Magstim Group since May 2017, a company that was formed through the merger of Magstim Ltd. and Technomed medical accessories. He has responsibility for establishing and executing a growth strategy for the transcranial magnetic stimulation and intra-operative nerve monitoring businesses globally.

Lothar was named Vice President & General Manager of the Medtronic Brain Modulation (DBS) business in May 2011. Responsibilities included establishing and executing a comprehensive, global business strategy for the DBS Therapies. In a prior role as Vice President, Research and Business Development at Medtronic Neuromodulation he was responsible for managing internal and external research programs. Krinke''s group managed drug infusion therapy programs funded by the Ventures Organization as well as Business Development and IP. Krinke has over 10 years of biomedical strategy expertise from top management consulting firms. He completed his postdoctoral as American Cancer Society Fellow at the California Institute of Technology and Krinke holds a Ph.D. in Molecular Biology from the University at Albany. Dr.Krinke received his undergraduate education at the Technische Univeritaet Braunschweig in Germany. He is the recipient of the Rumbough Award for Dedication to and Achievements in Diabetes research from the Juvenile Diabetes Research Foundation International.

dont miss

Future innovations in patient centric TMS technology and its clinical use

While TMS technology has been used for about 30 years primarily in research applications and for the last ten years in the clinical market there is much room for future innovation.
This presentation will suggest opportunities and challenges for broader adoption of TMS in clinical applications and suggest where technology development is already progressing and where further work is required. The presentation will specifically focus on patient needs and how patients might choose between different treatment options.
The presentation will discuss potential future indications as well as how technology can give access to more patients in today’s healthcare economic environment. Finally, future technologies that might eventually replace TMS will be mentioned.


  • Dr Neil Bindemann: Speaking at the European Neurological Convention

    Dr Neil Bindemann
    Primary Care and Community Neurology Society

    Why is the ‘Inflamed Mind’ relevant to neurological illness?

  • Dr Martine Stoffels: Speaking at the European Neurological Convention

    Dr Martine Stoffels
    Priory Brain Injury Services & Phoenix Mental Health Services

    r-TMS in neuropsychiatric conditions.

  • Martin Knight MD FRCS MBBS: Speaking at the European Neurological Convention

    Martin Knight MD FRCS MBBS
    The Spinal Foundation

    Indications and long-term outcomes for Transforaminal Endoscopic Lumbar Decompression and Foraminoplasty (TELDF)

  • Khashayar Pazooki: Speaking at the European Neurological Convention

    Khashayar Pazooki
    Groupe Psylux S.A. / Neuroacademy Luxembourg

    QEEG /ERP & psychometry into an individualized & personalized medicinal treatment Model of psychiatric disorders

  • Rosanne Tyas: Speaking at the European Neurological Convention

    Rosanne Tyas
    Royal Hospital for Neuro-disability

    Emotional Support and Adaption: Considering emotional aspects of music therapy with people with a neuro-disability.